B-cell regulation and its application to transplantation

Transplant International

Volumn 27, Issue 2, 2014, Pages 117-128

  Clatworthy, Menna R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

alloantibody; antibody mediated rejection; B cells; BAFF; regulatory B cells; rituximab

Indexed keywords

B CELL ACTIVATING FACTOR; CD22 ANTIGEN; CD40 LIGAND; FC RECEPTOR IIB; INTERLEUKIN 10;

ALLOGRAFT; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL SURVIVAL; CYTOKINE PRODUCTION; HOMEOSTASIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; REVIEW; TRANSPLANTATION;

ALLOANTIBODY; ANTIBODY-MEDIATED REJECTION; B CELLS; BAFF; REGULATORY B CELLS; RITUXIMAB;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD40; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL SURVIVAL; CELL TRANSPLANTATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1; INTERLEUKIN-10; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; RECEPTORS, IGG; SIALIC ACID BINDING IG-LIKE LECTIN 2; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84892364758     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12160     Document Type: Review

References (133)

1. Janeway CA Jr, Ron J, Katz ME,. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 1987; 138: 1051.
2. Ron Y, Sprent J,. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol 1987; 138: 2848.
3. Gonzalez M, Mackay F, Browning JL, Kosco-Vilbois MH, Noelle RJ,. The sequential role of lymphotoxin and B cells in the development of splenic follicles. J Exp Med 1998; 187: 997.
4. Golovkina TV, Shlomchik M, Hannum L, Chervonsky A,. Organogenic role of B lymphocytes in mucosal immunity. Science 1999; 286: 1965.
5. Ngo VN, Cornall RJ, Cyster JG,. Splenic T zone development is B cell dependent. J Exp Med 2001; 194: 1649.
6. Rauch PJ, Chudnovskiy A, Robbins CS, et al,. Innate response activator B cells protect against microbial sepsis. Science 2012; 335: 597.
7. Clatworthy MR,. Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11: 1359.
8. Bentall A, Cornell LD, Gloor JM, et al,. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76.
9. Stegall MD, Raghavaiah S, Gloor JM,. The (re)emergence of B cells in organ transplantation. Curr Opin Organ Transplant 2010; 15: 451.
10. Loupy A, Hill GS, Jordan SC,. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8: 348.
11. Dunn TB, Noreen H, Gillingham K, et al,. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132.
12. Sarwal M, Chua MS, Kambham N, et al,. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125.
13. Hippen BE, DeMattos A, Cook WJ, Kew CE 2nd, Gaston RS,. Association of CD20 + infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005; 5: 2248.
14. Tsai EW, Rianthavorn P, Gjertson DW, Wallace WD, Reed EF, Ettenger RB,. CD20 + lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation 2006; 82: 1769.
15. DiLillo DJ, Matsushita T, Tedder TF,. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010; 1183: 38.
16. Mauri C, Bosma A,. Immune regulatory function of B cells. Annu Rev Immunol 2012; 30: 221.
17. Pallier A, Hillion S, Danger R, et al,. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503.
18. Newell KA, Asare A, Kirk AD, et al,. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836.
19. Viklicky O, Krystufkova E, Brabcova I, et al,. B-cell-related biomarkers of tolerance are up-regulated in rejection-free kidney transplant recipients. Transplantation 2013; 95: 148.
20. Griffin DO, Holodick NE, Rothstein TL,. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20 + CD27 + CD43 + CD70. J Exp Med 2011; 208: 67.
21. Martin F, Kearney JF,. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001; 13: 195.
22. Parra D, Rieger AM, Li J, et al,. Pivotal advance: peritoneal cavity B-1 B cells have phagocytic and microbicidal capacities and present phagocytosed antigen to CD4 + T cells. J Leukoc Biol 2012; 91: 525.
23. Kyaw T, Tay C, Krishnamurthi S, et al,. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 2011; 109: 830.
24. Dunn-Walters DK, Isaacson PG, Spencer J,. Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells. J Exp Med 1995; 182: 559.
25. Blair PA, Norena LY, Flores-Borja F, et al,. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129.
26. Iwata Y, Matsushita T, Horikawa M, et al,. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530.
27. Ding Q, Yeung M, Camirand G, et al,. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest 2011; 121: 3645.
28. Cherukuri A, Salama A, Carter C, Clark B, Rothstein D, Baker R., Human regulatory B cells (BRegs) are Characterised by both IL-10 and TNF-α expression and are reduced in numbers with altered function in renal transplant recipients with immunological graft injury. Am J Transplant 2013; 13: 229.
29. Clark MR, Campbell KS, Kazlauskas A, et al,. The B cell antigen receptor complex: association of Ig-alpha and Ig-beta with distinct cytoplasmic effectors. Science 1992; 258: 123.
30. Sanchez M, Misulovin Z, Burkhardt AL, et al,. Signal transduction by immunoglobulin is mediated through Ig alpha and Ig beta. J Exp Med 1993; 178: 1049.
31. Gold MR, Law DA, DeFranco AL,. Stimulation of protein tyrosine phosphorylation by the B-lymphocyte antigen receptor. Nature 1990; 345: 810.
32. Carter RH, Fearon DT,. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992; 256: 105.
33. Roozendaal R, Carroll MC,. Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 2007; 219: 157.
34. Isnardi I, Ng YS, Menard L, et al,. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010; 115: 5026.
35. Lanzavecchia A, Sallusto F,. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 2007; 19: 268.
36. Pasare C, Medzhitov R,. Control of B-cell responses by Toll-like receptors. Nature 2005; 438: 364.
37. Scholz JL, Crowley JE, Tomayko MM, et al,. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 2008; 105: 15517.
38. Parsons RF, Vivek K, Redfield RR 3rd, et al,. B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev (Orlando) 2010; 24: 207.
39. Groom JR, Fletcher CA, Walters SN, et al,. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007; 204: 1959.
40. Liu YJ, Zhang J, Lane PJ, Chan EY, MacLennan IC,. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol 1991; 21: 2951.
41. Batista FD, Iber D, Neuberger MS,. B cells acquire antigen from target cells after synapse formation. Nature 2001; 411: 489.
42. Lund FE, Randall TD,. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010; 10: 236.
43. Noorchashm H, Reed AJ, Rostami SY, et al,. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006; 177: 7715.
44. Ng YH, Oberbarnscheidt MH, Chandramoorthy HC, Hoffman R, Chalasani G,. B cells help alloreactive T cells differentiate into memory T cells. Am J Transplant 2010; 10: 1970.
45. Jacob J, Kelsoe G,. In situ studies of the primary immune response to (4-hydroxy-3- nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J Exp Med 1992; 176: 679.
46. Lee SK, Rigby RJ, Zotos D, et al,. B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells. J Exp Med 2011; 208: 1377.
47. William J, Euler C, Leadbetter E, Marshak-Rothstein A, Shlomchik MJ,. Visualizing the onset and evolution of an autoantibody response in systemic autoimmunity. J Immunol 2005; 174: 6872.
48. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R,. Control systems and decision making for antibody production. Nat Immunol 2010; 11: 681.
49. Vinuesa CG, Linterman MA, Goodnow CC, Randall KL,. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 2010; 237: 72.
50. Crotty S,. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29: 621.
51. Thaunat O, Field AC, Dai J, et al,. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci USA 2005; 102: 14723.
52. Kerjaschki D, Regele HM, Moosberger I, et al,. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004; 15: 603.
53. Wehner JR, Fox-Talbot K, Halushka MK, Ellis C, Zachary AA, Baldwin WM 3rd,. B cells and plasma cells in coronaries of chronically rejected cardiac transplants. Transplantation 2010; 89: 1141.
54. Drayton DL, Liao S, Mounzer RH, Ruddle NH,. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006; 7: 344.
55. Pritchard NR, Smith KG,. B cell inhibitory receptors and autoimmunity. Immunology 2003; 108: 263.
56. Smith KGC, Clatworthy MR,. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10: 328.
57. Xiang Z, Cutler AJ, Brownlie RJ, et al,. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007; 8: 419.
58. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV,. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996; 379: 346.
59. Bolland S, Ravetch JV,. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13: 277.
60. Clatworthy MR, Smith KG,. FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J Exp Med 2004; 199: 717.
61. Clatworthy MR, Willcocks L, Urban B, et al,. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc Natl Acad Sci USA 2007; 104: 7169.
62. Brownlie RJ, Lawlor KE, Niederer HA, et al,. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb J Exp Med 2008; 205: 883.
63. Floto RA, Clatworthy MR, Heilbronn KR, et al,. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med 2005; 11: 1056.
64. Kono H, Kyogoku C, Suzuki T, et al,. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet 2005; 14: 2881.
65. Willcocks LC, Carr EJ, Niederer HA, et al,. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc Natl Acad Sci USA 2010; 107: 7881.
66. Nitschke L,. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev 2009; 230: 128.
67. O'Keefe TL, Williams GT, Batista FD, Neuberger MS,. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999; 189: 1307.
68. Sadaka B, Alloway RR, Shields AR, Schmidt NM, Woodle ES,. Proteasome inhibition for antibody-mediated allograft rejection. Semin Hematol 2012; 49: 263.
69. Everly MJ, Terasaki PI,. The state of therapy for removal of alloantibody producing plasma cells in transplantation. Semin Immunol 2012; 24: 143.
70. Locke JE, Magro CM, Singer AL, et al,. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231.
71. Lonze BE, Dagher NN, Simpkins CE, et al,. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010; 10: 2154.
72. Stegall MD, Diwan TS, Burns JM,. Prevention of acute humoral rejection with C5 inhibition [2009 ATC abstract 178]. Am J Transplant 2009; 9: 241.
73. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV,. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475: 110.
74. Schwab I, Nimmerjahn F,. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013; 13: 176.
75. Zarkhin V, Chalasani G, Sarwal MM,. The yin and yang of B cells in graft rejection and tolerance. Transplant Rev (Orlando) 2010; 24: 67.
76. Kamburova EG, Koenen HJ, Borgman KJ, Ten Berge IJ, Joosten I, Hilbrands LB,. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 2013; 13: 1503.
77. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A,. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837.
78. Vo AA, Peng A, Toyoda M, et al,. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
79. Donauer J, Wilpert J, Geyer M, et al,. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience. Xenotransplantation 2006; 13: 108.
80. Tyden G, Donauer J, Wadstrom J, et al,. Implementation of a Protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations. Transplantation 2007; 83: 1153.
81. Ichimaru N, Takahara S,. Japan's experience with living-donor kidney transplantation across ABO barriers. Nature Clinical Practice Nephrology 2008; 4: 682.
82. Kahwaji J, Sinha A, Toyoda M, et al,. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clinical Journal of the American Society of Nephrology: CJASN 2011; 6: 2894.
83. Sautenet B, Blancho G, Buchler M, et al,. One year results of the effects of Rituximab on acute humoral rejection in renal transplantation: RITUX ERAH, a multicentre randomized placebo controlled trial. Am J Transplant 2013; 13: 112.
84. Loupy A, Suberbielle-Boissel C, Zuber J, et al,. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403.
85. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K,. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469.
86. Tyden G, Genberg H, Tollemar J, et al,. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325.
87. Clatworthy MR, Watson CJ, Plotnek G, et al,. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683.
88. van den Hoogen M, Steenbergen E, Hoitsma A, Hilbrands L., Placebo-Controlled Trial. Am J Transplant 2013; 13: 112.
89. Tyden G, Ekberg H, Tufveson G, Mjornstedt L,. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation 2012; 94: e21.
90. Dilillo DJ, Griffiths R, Seshan SV, et al,. B lymphocytes differentially influence acute and chronic allograft rejection in mice. J Immunol 2011; 186: 2643.
91. Kim MJ, Kim HO, Kim HY, Park YM,. Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol 2009; 36: 284.
92. Ostergaard M, Baslund B, Rigby W, et al,. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010; 62: 2227.
93. Tedder TF,. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 572.
94. Gupta P, Goldenberg DM, Rossi EA, Chang CH,. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 2010; 116: 3258.
95. Vallera DA, Oh S, Chen H, Shu Y, Frankel AE,. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther 2010; 9: 1872.
96. Ye Q, Wang L, Wells AD, et al,. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 2004; 34: 2750.
97. Parsons RF, Yu M, Vivek K, et al,. Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator BLyS/BAFF. Transplantation 2012; 93: 676.
98. Xu H, He X, Sun J, Shi D, Zhu Y, Zhang X,. The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection. Transplant Proc 2009; 41: 112.
99. Xu H, He X, Liu Q, et al,. Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients. Transplant Proc 2009; 41: 1552.
100. Thaunat O, Patey N, Gautreau C, et al,. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008; 85: 1648.
101. Thibault-Espitia A, Foucher Y, Danger R, et al,. BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transplant 2012; 12: 2754.
102. Banham G, Prezzi D, Harford S, et al,. Elevated pre-transplant soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation 2013. [Epub ahead of print].
103. Lateef A, Petri M,. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010; 22: 504.
104. Ginzler EM, Wax S, Rajeswaran A, et al,. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012; 14: R33.
105. Henley T, Kovesdi D, Turner M,. B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur J Immunol 2008; 38: 3543.
106. Okkenhaug K, Bilancio A, Farjot G, et al,. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002; 297: 1031.
107. Bilancio A, Okkenhaug K, Camps M, et al,. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006; 107: 642.
108. Dil N, Marshall AJ,. Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation. Mol Immunol 2009; 46: 1970.
109. Lannutti BJ, Meadows SA, Herman SE, et al,. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591.
110. Banham-Hall E, Clatworthy MR, Okkenhaug K,. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 2012; 6: 245.
111. Ding BB, Bi E, Chen H, Yu JJ, Ye BH,. IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells. J Immunol 2013; 190: 1827.
112. Hillion S, Dueymes M, Youinou P, Jamin C,. IL-6 contributes to the expression of RAGs in human mature B cells. J Immunol 2007; 179: 6790.
113. Badell IR, Thompson PW, Turner AP, et al,. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant 2012; 12: 126.
114. Lowe M, Badell IR, Thompson P, et al,. A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am J Transplant 2012; 12: 2079.
115. Linterman MA, Beaton L, Yu D, et al,. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med 2010; 207: 353.
116. Zotos D, Coquet JM, Zhang Y, et al,. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 2010; 207: 365.
117. Bessa J, Kopf M, Bachmann MF,. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol 2010; 184: 4615.
118. Rodriguez-Bayona B, Ramos-Amaya A, Bernal J, Campos-Caro A, Brieva JA,. Cutting edge: IL-21 derived from human follicular helper T cells acts as a survival factor for secondary lymphoid organ, but not for bone marrow, plasma cells. J Immunol 2012; 188: 1578.
119. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K,. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007; 178: 3822.
120. Hippen KL, Bucher C, Schirm DK, et al,. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood 2012; 119: 619.
121. Mohr E, Serre K, Manz RA, et al,. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol 2009; 182: 2113.
122. Nishimoto N, Kishimoto T,. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619.
123. Callaghan CJ, Win TS, Motallebzadeh R, et al,. Regulation of Allograft Survival by Inhibitory FcgammaRIIb Signaling. J Immunol 2012; 189: 5694.
124. Rankin CT, Veri MC, Gorlatov S, et al,. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 2006; 108: 2384.
125. Zhou P, Comenzo RL, Olshen AB, et al,. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 2008; 111: 3403.
126. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR,. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.
127. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dorner T,. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008; 67: 450.
128. Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S,. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 2010; 116: 1698.
129. Schwab I, Seeling M, Biburger M, Aschermann S, Nitschke L, Nimmerjahn F,. B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo. Eur J Immunol 2012; 42: 3302.
130. Zhao G, Moore DJ, Lee KM, et al,. An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Am J Transplant 2010; 10: 796.
131. Yang M, Sun L, Wang S, et al,. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 2010; 184: 3321.
132. Yoshizaki A, Miyagaki T, DiLillo DJ, et al,. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012; 491: 264.
133. Hartung HP, Kieseier BC,. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 2010; 3: 205.